Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
Reinbold R, Hvinden IC, Rabe P, Herold RA, Finch A, Wood J, Morgan M, Staudt M, Clifton IJ, Armstrong FA, McCullagh JSO, Redmond J, Bardella C, Abboud MI, Schofield CJ.
Reinbold R, et al. Among authors: clifton ij.
Nat Commun. 2022 Aug 15;13(1):4785. doi: 10.1038/s41467-022-32436-4.
Nat Commun. 2022.
PMID: 35970853
Free PMC article.